Aurinia Pharmaceuticals Inc. Forecasted to Earn Q1 2025 Earnings of $0.05 Per Share (NASDAQ:AUPH)

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) – Stock analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Aurinia Pharmaceuticals in a research note issued on Thursday, August 1st. Leerink Partnrs analyst J. Schwartz expects that the biotechnology company will post earnings per share of $0.05 for the quarter. The consensus estimate for Aurinia Pharmaceuticals’ current full-year earnings is $0.15 per share. Leerink Partnrs also issued estimates for Aurinia Pharmaceuticals’ Q2 2025 earnings at $0.04 EPS, Q3 2025 earnings at $0.04 EPS and Q4 2025 earnings at $0.05 EPS.

Separately, StockNews.com raised Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Aurinia Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $10.00.

Aurinia Pharmaceuticals Stock Up 4.7 %

Shares of NASDAQ:AUPH opened at $5.62 on Monday. The stock’s 50-day moving average is $5.53 and its 200 day moving average is $5.72. The company has a market cap of $801.77 million, a PE ratio of -13.07 and a beta of 1.44. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.60 and a quick ratio of 5.05. Aurinia Pharmaceuticals has a 1 year low of $4.71 and a 1 year high of $10.24.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings results on Thursday, August 1st. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.01. The business had revenue of $57.10 million for the quarter, compared to analyst estimates of $54.25 million. Aurinia Pharmaceuticals had a negative net margin of 24.31% and a negative return on equity of 11.75%. The company’s revenue was up 37.6% on a year-over-year basis. During the same quarter last year, the firm earned ($0.08) EPS.

Institutional Trading of Aurinia Pharmaceuticals

Several large investors have recently bought and sold shares of the company. Armistice Capital LLC grew its holdings in Aurinia Pharmaceuticals by 57.7% in the fourth quarter. Armistice Capital LLC now owns 9,536,000 shares of the biotechnology company’s stock worth $85,729,000 after purchasing an additional 3,488,000 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Aurinia Pharmaceuticals by 39.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,048,456 shares of the biotechnology company’s stock worth $18,416,000 after acquiring an additional 576,120 shares in the last quarter. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter worth $2,089,000. GSA Capital Partners LLP increased its holdings in shares of Aurinia Pharmaceuticals by 196.1% during the first quarter. GSA Capital Partners LLP now owns 349,204 shares of the biotechnology company’s stock valued at $1,750,000 after acquiring an additional 231,260 shares in the last quarter. Finally, Nordea Investment Management AB raised its position in shares of Aurinia Pharmaceuticals by 51.7% in the 1st quarter. Nordea Investment Management AB now owns 308,500 shares of the biotechnology company’s stock worth $1,552,000 after purchasing an additional 105,100 shares during the last quarter. 36.83% of the stock is owned by institutional investors.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.